Convergence Of Clinical Trial Requirements Requires Flexibility Of Industry And Regulators – APEC Harmonization Workshop
This article was originally published in PharmAsia News
Regional harmonization may not be necessary as long as there is regulatory cooperation, says U.S. FDA.
You may also be interested in...
Japan's PMDA Considering Data Monitoring Committee Guidance, Weighs In On Adaptive Design - DIA Japan
TOKYO - Drug reviewers in Japan do not see as many adaptive trial designs as reviewers in the U.S., and to ensure data integrity for the potentially controversial trials companies should consult with the Pharmaceuticals and Medical Devices Agency as early as possible, an official said, while adding that regulatory guidance may soon be on the way
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.